710348-58-6

Usage

Uses

Used in Organic Synthesis:
(4-(2-(piperidin-1-yl)ethoxy)phenyl)boronic acid is used as a building block for the synthesis of complex organic molecules, leveraging its reactivity and structural features to create compounds with potential applications in various fields.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (4-(2-(piperidin-1-yl)ethoxy)phenyl)boronic acid is utilized for the development of new drugs, taking advantage of its ability to bind with biomolecules and its potential for targeted drug delivery.
Used in Drug Development:
(4-(2-(piperidin-1-yl)ethoxy)phenyl)boronic acid is employed as a valuable tool in drug development, where its interaction with biomolecules can lead to the discovery of new therapeutic agents and chemical probes.
Used in Pharmaceutical and Biotechnology Industries:
(4-(2-(piperidin-1-yl)ethoxy)phenyl)boronic acid is used across the pharmaceutical and biotechnology sectors for research and development, given its versatility and potential to contribute to the creation of innovative products and solutions.

Upstream product

• 836-58-8 1-[2-(4-bromophenoxy)ethyl]piperidine 
• 5419-55-6 Triisopropyl borate 
• 2008-75-5 N-chloroethylpiperidine hydrochloride 
• 269409-70-3 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol 

Downstream Products

• 767282-89-3 C₂₃H₂₆N₆O₂ 
• 1427186-59-1 (E)-1-(2-(4-(2-fluoro-1,2-diphenylvinyl)phenoxy)ethyl)piperidine 

Relevant academic research and scientific papers

Controlled Single and Double Iodofluorination of Alkynes with DIH- and HF-Based Reagents

A novel protocol for the regio- and stereoselective iodofluorination of internal and terminal alkynes using 1,3-diiodo-5,5,-dimethylhydantoin and HF-based reagents is disclosed. This approach is used to prepare a fluorinated tamoxifen derivative in two steps from commercially available starting materials. A facile method enabling controlled regioselective double iodofluorination of terminal alkynes is also presented.

Discovery of novel potent and highly selective glycogen synthase kinase-3β (GSK3β) inhibitors for Alzheimers Disease: Design, synthesis, and characterization of pyrazines

Glycogen synthase kinase-3β, also called tau phosphorylating kinase, is a proline-directed serine/threonine kinase which was originally identified due to its role in glycogen metabolism. Active forms of GSK3β localize to pretangle pathology including dystrophic neuritis and neurofibrillary tangles in Alzheimers disease (AD) brain. By using a high throughput screening (HTS) approach to search for new chemical series and cocrystallization of key analogues to guide the optimization and synthesis of our pyrazine series, we have developed highly potent and selective inhibitors showing cellular efficacy and bloo-brain barrier penetrance. The inhibitors are suitable for in vivo efficacy testing and may serve as a new treatment strategy for Alzheimers disease.

OXAZOLE TYROSINE KINASE INHIBITORS

The invention provides a compound which is an amide of the formula (1), or a salt, solvate, N-oxide or tautomer thereof; wherein: a is 0 or 1; b is 0 or 1 : provided that the sum of a and b is 0 or 1; T is O or NH Ar1 is a monocyclic or bicyclic 5- to 10-membered aryl or heteroaryl group containing up to 4 heteroatoms selected from O, N and S, and being optionally substituted by one or more substituents R1; Ar2 Js a monocyclic or bicyclic 5- to 10-membered aryl or heteroaryl group containing up to 4 heteroatoms selected from O, N and S and being optionally substituted by one or more substituents R2; and R1 and R2are as defined in the claims. The compounds are inhibitors of kinases and in particular FLT3, FLT4 and Aurora kinases.